echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > Gilead, Kite and oNKo-innate have teamed up

    Gilead, Kite and oNKo-innate have teamed up

    • Last Update: 2021-02-28
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    yesterday, Gilead Sciences and its Kite company, oNKo-innate, jointly announced that they had agreed to a three-year research collaboration on cancer immunotherapy to discover and develop the next generation of natural killer cells (NK) therapies.Current cancer immunotherapy methods focus on the anti-tumor immune response that activates T-cell-mediated. Like T cells, NK cells are a class of lymphocytes (white blood cells) that play an important role in the immune system. Both NK and T cells have the potential to attack cancer cells, but the mechanisms for killing tumor cells are different. Therefore, proper activation and targeting of NK cells may work in synergy with T-cell-mediated anti-tumor therapies.Under the terms of the agreement, oNKo-innate will receive an advance payment and will be eligible for additional payments based on potential clinical, regulatory and commercial milestones, as well as a share of future sales for this co-development therapy. oNKo-innate will use its genome-wide screening technology and its proprietary technology platform to help identify new immunotherapy targets that enhance the immune effectiveness of NK cells against tumors and to develop new NK cell therapies.“ Gilead Sciences is pleased to be working with oNKo-innate," said Dr. William Lee, Executive Vice President, Gilead Scientific Research. "
    (Drug Mingkangde
    )
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.